Endo sends BELBUCA back to BDSI

Endo International and BioDelivery Sciences International (BDSI) have agreed to return the BELBUCA buccal film product to BDSI.
According to the agreement, Endo will not receive any future royalty or milestone payments from BDSI. BDSI is also released from its obligation for future royalty payments.
"Since we entered into our licensing and development agreement with BDSI in 2012, the opioid market and Endo's strategic priorities have evolved," Endo President and CEO Paul Campanelli said. "While we continue to believe BELBUCA is a differentiated asset, the product no longer aligns with Endo's U.S.-branded segment strategy and our focus on core assets, including XIAFLEX, moving forward."
Campanelli said he is extremely grateful for the efforts of Endo's pain sales force.
The financial terms of the agreement have not been disclosed.